In hematologic malignancies, CD19/CD22 TanCARs have demonstrated preclinical efficacy against B-ALL, and a clinical study in 2020 evaluating CD19/CD20 TanCARs in refractory or relapsed B-cell lymphoma reported a 79% overall response rate, 71% complete response rate, and 64% progression-free survival rate [57–60]. This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.